The purpose of this study was to evaluate integrated 18 F-FDG PET/CT in patients with idiopathic pulmonary fibrosis (IPF) and diffuse parenchymal lung disease (DPLD). Methods: Thirty-six consecutive patients (31 men and 5 women; mean age 6 SD, 68.7 6 9.4 y) with IPF (n 5 18) or other forms of DPLD (n 5 18) were recruited for PET/CT and high-resolution CT (HRCT), acquired on the same instrument. The maximal pulmonary 18 F-FDG metabolism was measured as a standardized uptake value (SUV max ). At this site, the predominant lung parenchyma HRCT pattern was defined for each patient: ground-glass or reticulation/honeycombing. Patients underwent a global health assessment and pulmonary function tests. Results: Raised pulmonary 18 F-FDG metabolism in 36 of 36 patients was observed. The parenchymal pattern on HRCT at the site of maximal 18 F-FDG metabolism was predominantly ground-glass (7/36), reticulation/ honeycombing (26/36), and mixed (3/36). The mean SUV max in patients with ground-glass and mixed patterns was 2.0 6 0.4, and in reticulation/honeycombing it was 3.0 6 1.0 (MannWhitney U test, P 5 0.007). The mean SUV max in patients with IPF was 2.9 6 1.1, and in other DPLD it was 2.7 6 0.9 (MannWhitney U test, P 5 0.862). The mean mediastinal lymph node SUV max (2.7 6 1.3) correlated with pulmonary SUV max (r 5 0.63, P , 0.001). Pulmonary 18 F-FDG uptake correlated with the global health score (r 5 0.50, P 5 0.004), forced vital capacity (r 5 0.41, P 5 0.014), and transfer factor (r 5 0.37, P 5 0.042). Conclusion: Increased pulmonary 18 F-FDG metabolism in all patients with IPF and other forms of DPLD was observed. Pulmonary 18 F-FDG uptake predicts measurements of health and lung physiology in these patients. 18 F-FDG metabolism was higher when the site of maximal uptake corresponded to areas of reticulation/honeycomb on HRCT than to those with ground-glass patterns.